

Michael J Kelley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2166482/publications.pdf>

Version: 2024-02-01

180
papers

8,730
citations

81900

39
h-index

45317

90
g-index

186
all docs

186
docs citations

186
times ranked

11178
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. <i>Value in Health</i> , 2022, 25, 582-594.	0.3	6
2	Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 614.	3.7	23
3	Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100086.	2.1	3
4	Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now. <i>JCO Oncology Practice</i> , 2022, , OP2100693.	2.9	0
5	Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100461.	3.0	2
6	Clinical markers of successful liquid biopsy-based genomic profiling in veterans with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17031-e17031.	1.6	0
7	De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 55-63.	2.8	8
8	Frequency and outcomes of molecularly guided off-label targeted agent prescriptions in the VA National Precision Oncology Program (NPOP).. <i>Journal of Clinical Oncology</i> , 2022, 40, e18676-e18676.	1.6	0
9	Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. <i>Seminars in Oncology</i> , 2022, , .	2.2	1
10	Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program. <i>Pharmacogenomics</i> , 2021, 22, 137-144.	1.3	16
11	Transportation as a barrier to colorectal cancer care. <i>BMC Health Services Research</i> , 2021, 21, 332.	2.2	8
12	Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA. <i>JCO Precision Oncology</i> , 2021, 5, 638-645.	3.0	1
13	Cancer specialists in the VA as early adopters of clinical genetic services.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11029-11029.	1.6	0
14	Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17033-e17033.	1.6	1
15	Suicide risk following a new cancer diagnosis among veterans in Veterans Health Administration care.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12130-12130.	1.6	0
16	Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program. <i>JCO Oncology Practice</i> , 2021, 17, e1012-e1020.	2.9	8
17	Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2021, 21, 824.	2.6	3
18	EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100327.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. <i>Pharmacogenomics</i> , 2021, 22, 1121-1133.	1.3	5
20	Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population. <i>Blood</i> , 2021, 138, 4983-4983.	1.4	0
21	Medical oncologistsâ€™ perspectives of the Veterans Affairs National Precision Oncology Program. <i>PLoS ONE</i> , 2020, 15, e0235861.	2.5	5
22	Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program. <i>JCO Precision Oncology</i> , 2020, 4, 212-221.	3.0	19
23	Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 112-118.	2.5	14
24	Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7075-7075.	1.6	2
25	Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 52-58.	4.9	7
26	Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2005-2005.	1.6	1
27	Abstract PR11: Racial differences in characteristics of early- vs. late-onset colorectal cancer among veterans. , 2020, , .		0
28	VA National Precision Oncology Program. , 2020, 37, S22-S27.		0
29	National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016. <i>Journal of Oncology Practice</i> , 2019, 15, e568-e575.	2.5	8
30	<p>Cardiovascular disease-related chronic conditions among Veterans Affairs nonmetastatic colorectal cancer survivors: a matched caseâ€“control analysis<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6793-6802.	1.9	3
31	Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 127-139.	4.9	11
32	Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	7
33	Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 565-573.	0.8	4
34	Cancer Among Women Treated in the Veterans Affairs Healthcare System. <i>Journal of Women's Health</i> , 2019, 28, 268-275.	3.3	7
35	VA Cancer Research: A Legacy and A Future. <i>Seminars in Oncology</i> , 2019, 46, 305-307.	2.2	1
36	Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3074-3074.	1.6	5

#	ARTICLE	IF	CITATIONS
37	An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.. Journal of Clinical Oncology, 2019, 37, 318-318.	1.6	1
38	The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.. Journal of Clinical Oncology, 2019, 37, 193-193.	1.6	2
39	Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.. Journal of Clinical Oncology, 2019, 37, e23120-e23120.	1.6	0
40	Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. Clinical Breast Cancer, 2018, 18, 135-143.	2.4	4
41	Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions. Digestive Diseases and Sciences, 2018, 63, 1123-1138.	2.3	9
42	MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury and Migration. Journal of the American Society of Nephrology: JASN, 2018, 29, 155-167.	6.1	30
43	Modeling and Prediction of SIB Prostate IMRT Plans. International Journal of Radiation Oncology Biology Physics, 2018, 102, e541.	0.8	0
44	Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration. Hepatology Communications, 2018, 2, 1136-1146.	4.3	6
45	Chronic disease management perspectives of colorectal cancer survivors using the Veterans Affairs healthcare system: a qualitative analysis. BMC Health Services Research, 2018, 18, 171.	2.2	6
46	National trends in end of life care for veterans with advanced cancer.. Journal of Clinical Oncology, 2018, 36, 3-3.	1.6	1
47	Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis.. Journal of Clinical Oncology, 2018, 36, 741-741.	1.6	9
48	Cardiovascular disease-related chronic conditions among Veterans Affairs colorectal cancer survivors: A matched case-control analysis.. Journal of Clinical Oncology, 2018, 36, 4-4.	1.6	0
49	Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.. Journal of Clinical Oncology, 2018, 36, e24274-e24274.	1.6	0
50	Improved survival of small cell lung cancer in the veterans health administration from 2000-2010: Association with increasing utilization of PET staging.. Journal of Clinical Oncology, 2018, 36, e20571-e20571.	1.6	0
51	Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Internal Medicine, 2017, 177, 399.	5.1	280
52	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer—Response. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 977-977.	2.5	0
53	Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation, 2017, 35, 32-35.	1.3	17
54	Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. Clinical Lung Cancer, 2017, 18, 401-409.	2.6	10

#	ARTICLE	IF	CITATIONS
55	Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1814-1823.	1.1	31
56	Non-operative Management for Locally Advanced Rectal Cancer in the Veterans Health Administration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S67-S68.	0.8	0
57	Once Versus Twice Daily Fractionation for Limited Stage SCLC. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E442.	0.8	11
58	Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 71.	3.0	12
59	BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. <i>Familial Cancer</i> , 2017, 16, 41-49.	1.9	16
60	Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update. <i>Military Medicine</i> , 2017, 182, e1883-e1891.	0.8	98
61	Implementation of precision oncology in the Veterans Health Administration (VHA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6507-6507.	1.6	3
62	Short- and long-term outcomes of early stage non-small cell lung cancer (NSCLC) surgery.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8544-8544.	1.6	0
63	Cancer Care Collaborative Approach to Optimize Clinical Care. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2017, 34, S42-S49.	0.6	0
64	Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry. <i>Clinical Colorectal Cancer</i> , 2016, 15, e199-e204.	2.3	33
65	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	7.0	46
66	Survival With Stereotactic Body Radiation Therapy (SBRT) and Conventional Radiation Therapy (CRT) in Stage I Non-Small Cell Lung Cancer Patients in the Veterans Affairs System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S9.	0.8	2
67	Outcome Analysis of Treatment in Stage IIA, T3N0 Rectal Adenocarcinoma in the Veterans Health Administration (VHA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E186.	0.8	0
68	Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1672-1681.	1.1	60
69	CLINICAL IMPACT OF THE 21-GENE RS TEST WITHIN THE VETERANS HEALTH CARE ADMINISTRATION. <i>Value in Health</i> , 2016, 19, A312.	0.3	0
70	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1418-1425.	2.5	28
71	Readiness for Implementation of Lung Cancer Screening: A National Survey of VA Pulmonologists. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1794-1801.	3.2	15
72	Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e267-e267.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Second line treatment of small cell lung cancer: more is better?. Annals of Translational Medicine, 2016, 4, S65-S65.	1.7	5
74	Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World Journal of Gastroenterology, 2016, 22, 4732.	3.3	11
75	Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance). , 2016, , .		0
76	Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. Cancer, 2015, 121, 2578-2585.	4.1	31
77	Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians. Journal of Cancer Education, 2015, 30, 774-778.	1.3	4
78	Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer. Journal of Geriatric Oncology, 2015, 6, 202-210.	1.0	8
79	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer, 2015, 121, 1025-1031.	4.1	32
80	A Preliminary Exploration of College Smokers' Reactions to Nicotine Dependence Genetic Susceptibility Feedback. Nicotine and Tobacco Research, 2015, 17, 337-343.	2.6	14
81	A National Survey of Pulmonologists' Views on Low-Dose CT Screening for Lung Cancer. Annals of the American Thoracic Society, 2015, 12, 1667-75.	3.2	40
82	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non-Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data. Journal of Clinical Oncology, 2015, 33, 567-574.	1.6	114
83	Epidermal growth factor receptor (EGFR) testing among veterans diagnosed with lung cancer in the VA.. Journal of Clinical Oncology, 2015, 33, e17582-e17582.	1.6	0
84	Utilization of BRCA1/BRCA2 testing in Veterans Health Administration.. Journal of Clinical Oncology, 2015, 33, e17510-e17510.	1.6	0
85	Implementation of gene expression testing for breast cancer patients within the Veterans Health Administration.. Journal of Clinical Oncology, 2015, 33, e17511-e17511.	1.6	0
86	Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code Diagnoses. Journal of AIDS & Clinical Research, 2014, 05, 1000318.	0.5	30
87	Acting in the Face of Uncertainty. Annals of Internal Medicine, 2014, 161, 300.	3.9	9
88	Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans. BMJ Open Respiratory Research, 2014, 1, e000032.	3.0	1
89	Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration Data. Journal of Thoracic Oncology, 2014, 9, 702-709.	1.1	39
90	Adjuvant Chemotherapy for Older Patients With Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S12-S13.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma. <i>Human Genetics</i> , 2014, 133, 1289-1297.	3.8	54
92	Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. <i>Cancer</i> , 2014, 120, 1939-1947.	4.1	34
93	Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines. <i>Journal of Neurosurgery: Spine</i> , 2014, 21, 386-393.	1.7	17
94	Association between metformin (M) use and survival among non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7568-7568.	1.6	1
95	Metformin (M), diabetes (DM), and colorectal cancer (CRC) survival among U.S. veterans.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3535-3535.	1.6	0
96	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9612-9612.	1.6	0
97	Assessment of the Impact of Adjunctive Proactive Telephone Counseling to Promote Smoking Cessation among Lung Cancer Patients' Social Networks. <i>American Journal of Health Promotion</i> , 2013, 27, 181-190.	1.7	20
98	Influence of Comorbidity on Racial Differences in Receipt of Surgery Among US Veterans With Early-Stage Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 475-481.	1.6	35
99	Evolution of the Quality Oncology Practice Initiative Supportive Care Quality Measures Portfolio and Conformance at a Veterans Affairs Medical Center. <i>Journal of Oncology Practice</i> , 2013, 9, e86-e89.	2.5	3
100	Identification of repurposed small molecule drugs for chordoma therapy. <i>Cancer Biology and Therapy</i> , 2013, 14, 638-647.	3.4	32
101	Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206. <i>Journal of Thoracic Oncology</i> , 2013, 8, 102-108.	1.1	23
102	Abstract 352: Murine model of chordoma: Sonic Hedgehog promoter-driven Cre activation of Brachyury (T) expression induces spinal disk abnormalities and perinatal lethal developmental defects.., 2013, , .		0
103	Comparison of QOPI measure conformance between oncology fellows and attending physicians.. <i>Journal of Clinical Oncology</i> , 2013, 31, 162-162.	1.6	0
104	Tools to accurately identify veterans who undergo molecular diagnostic testing.. <i>Journal of Clinical Oncology</i> , 2013, 31, 201-201.	1.6	0
105	Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. <i>Blood</i> , 2012, 119, 238-250.	1.4	151
106	Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System. <i>Military Medicine</i> , 2012, 177, 693-701.	0.8	153
107	Impact of race on early-stage lung cancer treatment and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 232-232.	1.6	2
108	The evolution of supportive care quality measures portfolio and conformance.. <i>Journal of Clinical Oncology</i> , 2012, 30, 259-259.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Persistence of quality improvement in a Veterans Affairs (VA) academic practice assessed by Quality Oncology Practice Initiative (QOPI).. Journal of Clinical Oncology, 2012, 30, 209-209.	1.6	1
110	Mouse Models of Human MYH9-Related Diseases. Biophysical Journal, 2011, 100, 594a-595a.	0.5	0
111	Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemporary Clinical Trials, 2011, 32, 498-504.	1.8	18
112	Surveillance for Hepatocellular Carcinoma. Annals of Internal Medicine, 2011, 155, 274.	3.9	2
113	Automated extraction of Quality Oncology Practice Initiative (QOPI) quality measures from the Veterans Health Administration (VHA) electronic health record system.. Journal of Clinical Oncology, 2011, 29, e16560-e16560.	1.6	0
114	A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer) Tj ETQq0 0,0 rgBT /Overlock 10	1.1	46
115	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Medical Oncology, 2010, 27, 91-97.	2.5	15
116	Developing and Sustaining Quality Improvement Partnerships in the VA: The Colorectal Cancer Care Collaborative. Journal of General Internal Medicine, 2010, 25, 38-43.	2.6	44
117	Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. Journal of Pathology, 2010, 220, 608-617.	4.5	41
118	Molecular Characterization of Putative Chordoma Cell Lines. Sarcoma, 2010, 2010, 1-14.	1.3	56
119	Quality of Nonmetastatic Colorectal Cancer Care in the Department of Veterans Affairs. Journal of Clinical Oncology, 2010, 28, 3176-3181.	1.6	61
120	A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6994-6999.	7.1	306
121	T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nature Genetics, 2009, 41, 1176-1178.	21.4	284
122	Persistent Smoking After a Diagnosis of Lung Cancer Is Associated With Higher Reported Pain Levels. Journal of Pain, 2009, 10, 323-328.	1.4	81
123	Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1117-1125.	1.1	40
124	Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation, 2008, 118, 3930-42.	8.2	1,225
125	Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI). Journal of Clinical Oncology, 2008, 26, 6578-6578.	1.6	1
126	Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B. Journal of Clinical Oncology, 2007, 25, 1698-1704.	1.6	437

#	ARTICLE	IF	CITATIONS
127	Lung Cancer Chemoprevention. <i>Chest</i> , 2007, 132, 56S-68S.	0.8	30
128	A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 570-580.	27.0	577
129	Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 431-432.	2.0	10
130	Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care. <i>Journal of Thoracic Oncology</i> , 2006, 1, 692-696.	1.1	17
131	Genomic signatures to guide the use of chemotherapeutics. <i>Nature Medicine</i> , 2006, 12, 1294-1300.	30.7	557
132	Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. <i>Blood</i> , 2005, 105, 161-169.	1.4	79
133	Genotype-phenotype correlation in MYH9-related thrombocytopenia. <i>British Journal of Haematology</i> , 2005, 130, 620-627.	2.5	86
134	Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs). <i>International Journal of Cancer</i> , 2005, 116, 487-491.	5.1	30
135	Retrospective family study of childhood medulloblastoma. <i>American Journal of Medical Genetics, Part A</i> , 2005, 134A, 399-403.	1.2	27
136	Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5099-5107.	1.6	167
137	Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 892-899.	2.5	34
138	P-339 Multidisciplinary versus traditional evaluation in sequential patient cohorts with lung cancer. <i>Lung Cancer</i> , 2005, 49, S205.	2.0	0
139	Expression of HIF-1 α , CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 325-335.	2.0	159
140	Erythropoietin and Erythropoietin Receptor Expression in Early Stage Non-Small Cell Lung Cancer: Prognostic Significance. <i>Blood</i> , 2005, 106, 4258-4258.	1.4	2
141	Carbonic Anhydrase IX in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7925-7933.	7.0	87
142	Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy—from bench to patient bedside. <i>Seminars in Oncology</i> , 2004, 31, 4-21.	2.2	33
143	Molecular classification and molecular genetics of human lung cancers. <i>Seminars in Oncology</i> , 2004, 31, 4-19.	2.2	56
144	Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 7005-7005.	1.6	36

#	ARTICLE	IF	CITATIONS
145	Ritterazine ^{AB} , a new cytotoxic natural compound, induces apoptosis in cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 202-208.	2.3	32
146	Screening for Lung Cancer*. <i>Chest</i> , 2003, 123, 72S-82S.	0.8	242
147	Assessment of the Scope and Quality of Clinical Practice Guidelines in Lung Cancer*. <i>Chest</i> , 2003, 123, 7S-20S.	0.8	66
148	Prevention of Lung Cancer*. <i>Chest</i> , 2003, 123, 50S-59S.	0.8	36
149	Etiology of the Mutational Spectrum of ras Genes in Human Carcinomas. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1516-1517.	6.3	4
150	Familial Chordoma, a Tumor of Notochordal Remnants, Is Linked to Chromosome 7q33. <i>American Journal of Human Genetics</i> , 2001, 69, 454-460.	6.2	71
151	Genetic Changes in Contralateral Bronchioloalveolar Carcinomas of the Lung. <i>Oncology</i> , 2001, 60, 81-87.	1.9	9
152	Genetic Analysis of the β -Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1886-1888.	6.3	89
153	MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. , 2000, 28, 58-65.		68
154	Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. <i>Nature Genetics</i> , 2000, 26, 106-108.	21.4	237
155	Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. <i>Human Genetics</i> , 2000, 106, 557-564.	3.8	8
156	Human Nonsyndromic Hereditary Deafness DFNA17 Is Due to a Mutation in Nonmuscle Myosin MYH9. <i>American Journal of Human Genetics</i> , 2000, 67, 1121-1128.	6.2	152
157	Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. <i>Human Genetics</i> , 2000, 106, 557-564.	3.8	16
158	Human Nonsyndromic Hereditary Deafness DFNA17 Is Due to a Mutation in Nonmuscle Myosin MYH9. <i>American Journal of Human Genetics</i> , 2000, 67, 1121-1128.	6.2	190
159	Genomic structure of theEPHA1receptor tyrosinekinase gene. <i>Molecular and Cellular Probes</i> , 1999, 13, 169-173.	2.1	13
160	Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. <i>Oncogene</i> , 1998, 17, 1019-1026.	5.9	23
161	Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines1The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Navy or the Department of Defense. This is a US Government work. There are no restrictions on its use.1. <i>Lung Cancer</i> , 1998, 21, 165-175.	2.0	13
162	Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. <i>International Immunology</i> , 1997, 9, 1085-1093.	4.0	7

#	ARTICLE	IF	CITATIONS
163	Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6770-6775.	7.1	387
164	Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.. Journal of Clinical Oncology, 1997, 15, 735-743.	1.6	24
165	Fluorescence <i>in situ</i> hybridization analysis of keratinocyte growth factor gene amplification and dispersion in evolution of great apes and humans. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11461-11465.	7.1	56
166	Antitumor Activity of a Monoclonal Antibody Directed Against Gastrin-Releasing Peptide in Patients With Small Cell Lung Cancer. Chest, 1997, 112, 256-261.	0.8	103
167	Retreatment of Patients Surviving Cancer-Free 2 or More Years After Initial Treatment of Small Cell Lung Cancer. Chest, 1996, 110, 165-171.	0.8	23
168	Mutation of p53 gene in hepatocellular carcinoma cell lines with HBV DNA. , 1996, 67, 898-902.		37
169	Biology and Molecular Genetics of Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 1996, 17, 299-308.	2.1	3
170	CDKN2 in HPV positive and HPV negative cervical carcinoma cell lines. International Journal of Cancer, 1995, 63, 226-230.	5.1	40
171	TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. International Journal of Cancer, 1995, 64, 229-233.	5.1	25
172	Differential Inactivation of CDKN2 and Rb Protein in Non-Small-Cell and Small-Cell Lung Cancer Cell Lines. Journal of the National Cancer Institute, 1995, 87, 756-761.	6.3	81
173	Biology of small cell lung cancer. Lung Cancer, 1995, 12, S5-S16.	2.0	10
174	Anticancer antibodies for lung cancer.. Journal of Clinical Oncology, 1994, 12, 2519-2520.	1.6	1
175	Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides. Cancer Letters, 1994, 81, 19-25.	7.2	27
176	Calcitonin elevation in small cell lung cancer without ectopic production.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 183-190.	5.6	18
177	Overview of Genetic and Molecular Events in the Pathogenesis of Lung Cancer. Chest, 1993, 103, 1S-3S.	0.8	36
178	Emergence of the keratinocyte growth factor multigene family during the great ape radiation.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9287-9291.	7.1	33
179	Effects of intracoronary administration of contrast materials on left ventricular function in the presence of severe coronary artery stenosis. CardioVascular and Interventional Radiology, 1981, 4, 110-116.	2.0	14
180	Direct Myocardial Effects of Intracoronary Administration of New Contrast Materials with Low Osmolality. Investigative Radiology, 1980, 15, 39-46.	6.2	50